Advertisement

Topics

Gilenya patent decision gives MS market a reprieve

06:24 EDT 13 Jul 2018 | BioPharmaDive

A favorable decision from an IPR hearing could delay a generic version of Novartis' oral multiple sclerosis drug, potentially helping rivals as well. 

Original Article: Gilenya patent decision gives MS market a reprieve

NEXT ARTICLE

More From BioPortfolio on "Gilenya patent decision gives MS market a reprieve"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Hearing
Hearing, auditory perception, or audition is the ability to perceive sound by detecting vibrations, changes in the pressure of the surrounding medium through time, through an organ such as the ear. Sound may be heard through solid, liquid, or gaseous mat...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...